CLINICAL TRIALS PROFILE FOR PRIDOPIDINE

Clinical Trials for Pridopidine

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00665223 ↗	A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 3	The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.
NCT00665223 ↗	A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease	Completed	Teva Pharmaceutical Industries	Phase 3	The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.
NCT00724048 ↗	A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2/Phase 3	The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
NCT00724048 ↗	A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease	Completed	Teva Pharmaceutical Industries	Phase 2/Phase 3	The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
NCT01306929 ↗	Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease	Completed	Prilenia	Phase 2	Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment.
NCT01306929 ↗	Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease	Completed	Teva Branded Pharmaceutical Products, R&D Inc.	Phase 2	Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment.
NCT02006472 ↗	A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease	Completed	European Huntington's Disease Network	Phase 2	This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).

Clinical Trial Conditions for Pridopidine

Condition Name

Condition Name
Intervention	Trials
Amyotrophic Lateral Sclerosis	3
Huntington Disease	3
Huntington's Disease	3
Health Volunteers, Huntington Disease	1

Condition MeSH

Condition MeSH
Intervention	Trials
Huntington Disease	7
Amyotrophic Lateral Sclerosis	3
Motor Neuron Disease	2
Parkinson Disease	1

Clinical Trial Locations for Pridopidine

Trials by Country

Trials by Country
Location	Trials
United States	114
Canada	15
United Kingdom	11
Germany	9
France	7

Trials by US State

Trials by US State
Location	Trials
New York	7
Washington	7
Pennsylvania	7
Maryland	6
Colorado	6

Clinical Trial Progress for Pridopidine

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
PHASE3	1
Phase 3	2
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	5
Terminated	2
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for Pridopidine

Sponsor Name

Sponsor Name
Sponsor	Trials
Prilenia	7
Teva Branded Pharmaceutical Products, R&D Inc.	4
Merit E. Cudkowicz, MD	2

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	17
Other	6